NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis $3.38 -0.18 (-5.06%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$3.38 0.00 (0.00%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bicycle Therapeutics Stock (NASDAQ:BCYC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bicycle Therapeutics alerts:Sign Up Key Stats Today's Range$3.33▼$3.7050-Day Range$3.38▼$4.3952-Week Range$3.33▼$9.16Volume728,668 shsAverage Volume437,341 shsMarket Capitalization$236.57 millionP/E RatioN/ADividend YieldN/APrice Target$13.86Consensus RatingHold Company Overview Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Bicycle technology. The platform uses small, constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and manufacturing advantages of small molecules with the target specificity often associated with larger biologic medicines. The company’s research and development activities are focused primarily on oncology. Its pipeline includes Bicycle toxin conjugates, which are designed to deliver cancer-killing payloads to tumor cells, as well as Bicycle molecules intended to modulate immune targets and support other targeted therapeutic approaches. Bicycle Therapeutics has also pursued collaborations and partnered programs to apply its platform across a range of disease areas. Bicycle Therapeutics was founded in 2009 based on research originating at the University of Cambridge and maintains operations in Cambridge, England, and the United States. The company’s programs are developed for potential use in international markets, although most remain in clinical or preclinical development and are subject to regulatory review. Kevin Lee serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Bicycle Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreBCYC MarketRank™: Bicycle Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 412th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingBicycle Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialBicycle Therapeutics has a consensus price target of $13.86, representing about 310.0% upside from its current price of $3.38.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Bicycle Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($2.26) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bicycle Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.10% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 6.68.Change versus previous monthShort interest in Bicycle Therapeutics has recently increased by 1.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.34 News SentimentBicycle Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bicycle Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for BCYC on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,567.00 in company stock.Percentage Held by Insiders22.00% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCYC Stock News HeadlinesAnalyzing Aktis Oncology (NASDAQ:AKTS) & Bicycle Therapeutics (NASDAQ:BCYC)October 2 at 4:15 AM | americanbankingnews.comBicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of "Hold" from AnalystsSeptember 27, 2026 | americanbankingnews.comThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story. | Stansberry Research (Ad)Bicycle Therapeutics Ltd. ADRSeptember 24, 2026 | barrons.comRBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)August 5, 2026 | theglobeandmail.comVisa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatchAugust 3, 2026 | pymnts.comBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial ResultsJuly 30, 2026 | finance.yahoo.comBicycle Therapeutics (NASDAQ:BCYC) Stock, Earnings Estimates, EPS, And RevenueJuly 14, 2026 | benzinga.comSee More Headlines BCYC Stock Analysis - Frequently Asked Questions How have BCYC shares performed this year? Bicycle Therapeutics' stock was trading at $7.08 on January 1st, 2026. Since then, BCYC stock has decreased by 52.3% and is now trading at $3.38. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) posted its quarterly earnings data on Thursday, July, 30th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.14. The company earned $0.63 million during the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 33.22% and a negative net margin of 311.11%. When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $65 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,333,333 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Curaleaf (CURLF) and Company Calendar Last Earnings7/30/2026Today10/03/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (54m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BCYC's financial health is in the Red zone, according to TradeSmith. BCYC has been in this zone for over 54 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCYC CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees288Year Founded2009Price Target and Rating Average Price Target for Bicycle Therapeutics$13.86 High Price Target$36.00 Low Price Target$7.00 Potential Upside/Downside+310.0%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$218.96 million Net Margins-311.11% Pretax Margin-308.27% Return on Equity-33.22% Return on Assets-27.79% Debt Debt-to-Equity RatioN/A Current Ratio12.08 Quick Ratio12.08 Sales & Book Value Annual Sales$72.86 million Price / Sales3.25 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book0.38Miscellaneous Outstanding Shares69,990,000Free Float54,595,000Market Cap$236.57 million OptionableOptionable Beta1.68 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BCYC) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredLarry's Three-Step Strategy Revealed at The Dollar Trap SummitLarry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocu...Brownstone Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts